Advanced in Alveolar Soft Part Sarcoma

Dr. Monica M. Bertagnolli

General Surgery | Surgical Oncology
75 Francis St, Carrie Hall 116, 
Boston, MA 
Advanced in Alveolar Soft Part Sarcoma
75 Francis St, Carrie Hall 116, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Monica Bertagnolli is a General Surgeon and a Surgical Oncologist in Boston, Massachusetts. Dr. Bertagnolli is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Desmoid Tumor, Gastrointestinal Stromal Tumor, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, and Gastrectomy.

Her clinical research consists of co-authoring 115 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Surgery
Surgical Oncology
Licenses
Surgery in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

75 Francis St, Carrie Hall 116, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Apalutamide, LHRH Analogue, Abiraterone acetate, Prednisone
Study Phase: Phase 3
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: Darolutamide, Enzalutamide
Study Phase: Phase 2
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Study Phase: Phase 2
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
View 6 Less Clinical Trials

115 Total Publications

Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration.
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration.
Journal: JAMA network open
Published: June 17, 2025
Similar Doctors
Distinguished in Alveolar Soft Part Sarcoma
Dr. John T. Mullen
General Surgery | Surgical Oncology
Distinguished in Alveolar Soft Part Sarcoma
Dr. John T. Mullen
General Surgery | Surgical Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Mullen is a General Surgeon and a Surgical Oncologist in Boston, Massachusetts. Dr. Mullen is rated as an Elite provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Retroperitoneal Liposarcoma, Gastrectomy, and Colostomy. Dr. Mullen is currently accepting new patients.

Distinguished in Alveolar Soft Part Sarcoma
Dr. Chandrajit Raut
General Surgery | Surgical Oncology
Distinguished in Alveolar Soft Part Sarcoma
Dr. Chandrajit Raut
General Surgery | Surgical Oncology

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (0.1 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chandrajit Raut is a General Surgeon and a Surgical Oncologist in Boston, Massachusetts. Dr. Raut is rated as an Elite provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Nephrectomy, and Pancreaticoduodenectomy.

Distinguished in Alveolar Soft Part Sarcoma
Dr. Jiping Wang
Surgical Oncology
Distinguished in Alveolar Soft Part Sarcoma
Dr. Jiping Wang
Surgical Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3586
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jiping Wang is a Surgical Oncologist in Boston, Massachusetts. Dr. Wang is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Stomach Cancer, Familial Pancreatic Cancer, Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Wang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bertagnolli's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile